Novel biological therapeutic approaches to cutaneous lupus erythematosus

Abstract

Cutaneous lupus erythematosus (CLE) encompasses a spectrum of dermatologic manifestations which can occur with or without systemic lupus erythematosus (SLE). Treatment of CLE is challenging as the traditional treatments are off label and often fail and there is no drug specifically approved for CLE. The knowledge gained from the emerging trials on biologic therapy in SLE has provided insight into the utility of biologic therapy for CLE. Areas covered: An overview is provided on the biological agents studied for CLE discussing their immunological target, their efficacy in treating the various CLE manifestations and the outcome measures used. Expert opinion: There is a paucity of trials dedicated to the biologic treatment of CLE. Several of the described biological treatments' efficacy suggests that different clinical phenotypes of CLE may require different immunological targeted therapies. Recently published and ongoing trials of SLE focusing on novel agents for CLE using the Cutaneous Lupus Area and Severity Index (CLASI) as the outcome measure have shown promising results. Further trials designed specifically to study the efficacy of biologic treatment in CLE subgroups with or without systemic involvement using specific metrics for assessing cutaneous involvement are needed and will aid in illuminating the role of biologic therapy in CLE.

Cutaneous manifestations of pediatric systemic lupus erythematosus

“…20,21 Biologics: Biotherapy is another therapeutic line to be used in cases of skin damage that is refractory to the usual treatments; although the results with certain biologics such as JAK inhibitors, are encouraging in adults, larger studies are needed to assess the effectiveness in children. 22,23…”